The short answer
Dalteparin can raise blood potassium. Adding potassium may increase concern, particularly when kidney function is reduced or potassium is already high. The combination needs an individual intake and monitoring plan, not automatic replacement or restriction.
What this answer covers
Oral potassium with subcutaneous dalteparin sodium. Potassium chloride supplies potassium; sodium in the injection is a separate constituent, not the cause of this potassium-load interaction.
- Supplement or preparation
- Potassium
- Medication ingredient
- dalteparin
Why blood potassium can rise
Dalteparin’s US label lists high potassium among postmarketing reports. Pfizer’s Indian label explicitly explains that dalteparin can suppress aldosterone, a hormone involved in potassium regulation. Diabetes, kidney impairment, acidosis and other potassium-raising medicines can increase concern.
Direct dalteparin evidence has limits
A hospital-record study reported high potassium in 17.2% of 343 dalteparin recipients, all treated for clot prevention. This was lower than in the unfractionated-heparin group. Different patient characteristics, other medicines and unmeasured dietary intake limit causal conclusions; the figure is not a risk estimate for adding a supplement.
Check the actual potassium source
Potassium chloride contributes elemental potassium and is also found in some salt substitutes. Other potassium salts also add potassium, while sodium chloride is different. Review the labeled potassium amount and all overlapping products. These findings do not justify restricting every potassium-containing food.
Monitoring is more useful than spacing
People at risk may need blood potassium checked before and during dalteparin treatment. The clinician should decide whether prescribed potassium remains necessary. Separating an oral dose from the injection has not been established to prevent potassium accumulation; do not stop prescribed treatment or change dalteparin yourself.
Evidence and practical considerations
Side effects & toxicity
Exact dalteparin label and observational potassium evidence support a conditional potassium-load precaution, not a measured supplement-specific incidence or universal restriction.
- Exact scope
- Oral potassium with subcutaneous dalteparin sodium. Potassium chloride supplies potassium; sodium in the injection is a separate constituent, not the cause of this potassium-load interaction. with Subcutaneous dalteparin sodium; active ingredient bridge to RxCUI67109 IN. Not UFH or another LMWH.
- Medication form and route
- subcutaneous dalteparin; oral supplement
What remains uncertain
- Source-specific population, preparation and endpoint limits apply; no universal dose or timing rule.
Factors that may matter: Exact preparation; Dose and duration; Kidney function; Other medicines.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients receiving subcutaneous dalteparin sodium.
Bleeding risk can increase with platelet inhibitors and other anticoagulants. Hyperkalemia is listed among postmarketing reports, whose frequency and causal relationship cannot reliably be established.
How this applies: Exact dalteparin sodium injection product and route; no silent transfer of unfractionated-heparin dosing or monitoring rules.
Does not specifically name these supplements. Not unfractionated heparin, another LMWH, an oral anticoagulant or topical therapy.
Source 2: current product label
labeling.pfizer.com · Source check Sep 10, 2026
Population: Patients receiving subcutaneous dalteparin sodium.
Dalteparin can suppress aldosterone and raise potassium, especially with diabetes, renal failure, acidosis, already high potassium or potassium-sparing drugs. Advises baseline and ongoing potassium checks in people at risk. Sodium content is a separate formulation issue.
How this applies: Exact dalteparin sodium injection product and route; no silent transfer of unfractionated-heparin dosing or monitoring rules.
Regulatory class-mechanism precaution explicitly including dalteparin; does not measure an oral potassium supplement interaction or provide a universal safe intake.
Source 3: original observational human study
pmc.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 929 hospitalized adults, including 343 dalteparin recipients, all receiving prophylaxis.
Reported potassium above 5.3 mmol/L in 17.2% of dalteparin recipients, lower than the UFH group. This is an association, not a supplement interaction estimate.
How this applies: Exact medication evidence for potassium concern, not direct dalteparin plus potassium supplementation evidence.
No randomized comparison, no dietary potassium assessment, substantial baseline and treatment differences; UFH patients older and more often had kidney disease. Table 2 has an internal inconsistency between dalteparin total events and severity counts; avoid severity-specific estimates. No oral potassium challenge.
Source 4: regulatory guidance
ods.od.nih.gov · Source check Sep 10, 2026
Population: Users of the specified preparation.
Reduced potassium excretion raises hyperkalemia risk; supplement and salt-substitute amounts matter. People at risk should discuss intake from all sources.
How this applies: Exact species, preparation, route and measured endpoints govern applicability; other anticoagulants are not silently treated as heparin.
No heparin-specific supplement dose-response threshold; not a universal food restriction.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Prepared exact dalteparin article with independently checked product label and explicit limits on indirect supplement evidence. | |
| Research summary published |
Article revision: a49b3ae9be3a1deb
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.